Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

The Cannigma

FEBRUARY 1, 2023

Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. Use harm reduction techniques (i.e.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. To access a complete photo gallery of this historic grow, please click here.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The live webcast can be accessed here and on the investor page of Marinus’ website. Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 10, 2022

11 May 2022. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions. Here’s the Uni of Sydney press release.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JANUARY 19, 2022

January 17, 2022. – January 17, 2022) – Psygen Industries Ltd. received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “). received a dealer’s licence issued by Health Canada on January 17, 2022 (the “ Dealer’s Licence “).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

FEBRUARY 3, 2022

Together with its wide network of research partners, MediCane is executing clinical programs to develop cannabis-based drugs with two leading therapeutic areas – Behavioral and Psychological Symptoms of Dementia (BPSD) and sleep disorders.

Clinical Trials 52

Clinical Trials Research and Development Packaging Oil 52

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Applicants must also authorize their training program to conduct a criminal background check. Conducting a Psilocybin Administration Session (20 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

MARCH 3, 2022

If everything works out in the production and research phase, there is a clause in the license that will allow it to be expanded to clinical trials. The eventual trials would target PTSD, addiction, alcoholism, depression, and anxiety. This would add to the wave of research beginning in the U.S. and Europe.

Research and Development 52

Research and Development Medicine Clinical Trials Microdosing 52

Cannabis Law Report

NOVEMBER 29, 2021

The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD. TRD is just the beginning.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

MAY 1, 2022

We note nearly half (49%) of the respondents to your Community Interest Survey indicated that their interest in accessing psilocybin under Measure 109 was for spiritual purposes. In other words, the agency is empowered to adopt rules that promote other values such as the free exercise of religion or the accessibility of psilocybin services.

Safety 52

Safety History Programs Clinical Trials 52

Cannabis Law Report

JULY 21, 2022

JULY 21, 2022. By decriminalizing cannabis at the federal level, the CAOA also ensures that state-legal cannabis businesses or those in adjacent industries will no longer be denied access to bank accounts or financial services simply because of their ties to cannabis. Hopefully i’ll be dead by then.

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

DECEMBER 21, 2021

Prakat swiftly modernizes legacy business hardware, software programs, and downloadable apps. The school’s new location will be opening up in Q1 of 2022 to further ease the shortage and tension of much-needed healthcare workers. Yet, more than half of the people in the least developed countries lack access to electricity.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52